Statins are the preferred agent for lowering low-density lipoprotein cholesterol and reducing the risk of cardiovascular events, according to a new review. Study authors suggest, however, that other interventions, especially those that act predominantly through upregulation of LDL receptor expression, might provide additional options.

Opposition to Pharmacy Substitution Is One Barrier to Broader Biosimilar Use

Despite FDA-approved biosimilars in the U.S. market, the products are not used here as often as in some European countries, according to a new survey. Find out how unwillingness to allow pharmacy-level substitution is a factor.